Seminars in Cancer Biology

Article	Citations
Editorial Board	436
Editorial Board	407
Deregulated transcription factors in the emerging cancer hallmarks	312
Targeting Hippo signaling pathway by phytochemicals in cancer therapy	238
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation	234
The molecular chaperone TRAP1 in cancer: From the basics of biology to pharmacological targeting	214
Critical DNA damaging pathways in tumorigenesis	212
Multifaceted role of chemokines in solid tumors: From biology to therapy	207
Advances in biology and novel treatments of SCLC	204
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	202
Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications	187
Small secretory proteins of immune cells can modulate gynecological cancers	185
Emerging applications of bacteria as antitumor agents	183
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	181
Editorial Board	178
Special issue: Deregulated transcription factors in the cancer therapeutic challenges: An update on cancer stemness features	174
Editorial Board	172
Gut microbes in gastrointestinal cancers	171
PIWI-interacting RNAs in human cancer	169
Excess body weight and postmenopausal breast cancer: Emerging molecular mechanisms and perspectives	159
Erratum to “RNA regulatory mechanisms controlling TGF-β signaling and EMT in cancer” [Semin. Cancer Biol. 102–103 (2024) 4–16]	159
Innovative trial design in precision oncology	156
Immune cellular components and signaling pathways in the tumor microenvironment	150
Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse	142
Thinking small to win big? A critical review on the potential application of extracellular vesicles for biomarker discovery and new therapeutic approaches in pancreatic cancer	138

Anticancer properties of chimeric HDAC and kinase inhibitors	136
Association of Chlamydia and Mycoplasma infections with susceptibility to ovarian cancer: A systematic review and meta-analysis	136
Origins and molecular effects of hypoxia in cancer	135
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy	132
Microbiome dysbiosis and epigenetic modulations in lung cancer: From pathogenesis to therapy	130
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives	128
Extracellular vesicles associated microRNAs: Their biology and clinical significance as biomarkers in gastrointestinal cancers	127
Genome chaos: Creating new genomic information essential for cancer macroevolution	123
The IL-1 family in tumorigenesis and antitumor immunity	120
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	118
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	118
New biological and immunological approaches to cancer therapy: Basic and clinical aspects	116
Reprogramming of glycolysis by chemical carcinogens during tumor development	115
Cellular stress responses and metabolic reprogramming in cancer progression and dormancy	109
Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer	109
Therapy-induced modulation of extracellular vesicles in hepatocellular carcinoma	108
Vibrational spectroscopy for decoding cancer microbiota interactions: Current evidence and future perspective	107
Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy	106
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools	106
Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systems	106
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	105
The intricacies of NRF2 regulation in cancer	105
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	104
Metabolic landscape and rewiring in normal hematopoiesis, leukemia and aging	102
Editorial Board	102
Atrial fibrillation in cancer patients: Epidemiology, identification and management	102
Anticancer natural products targeting immune checkpoint protein network	102
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	101
Targeting the “undruggable”: RNA-binding proteins in the spotlight in cancer therapy	101
The role of deiodinases on metabolic alteration in cancer	101
Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways	99
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	97
How far have we explored fungi to fight cancer?	97
Insight into the role of multiple signaling pathways in regulating cancer stem cells of gynecologic cancers	97
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	93
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	92
The role of RNA processing and regulation in metastatic dormancy	91
Editorial Board	91
Cytotoxic activity of l-lysine alpha-oxidase against leukemia cells	91
Editorial Board	91
Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications	90
The foundational framework of tumors: Gametogenesis, p53, and cancer	89
Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer	89
Metabolic reprogramming of tumor microenviroment by engineered bacteria	87
Role of ubiquitination-driven metabolisms in oncogenesis and cancer therapy	86
Mechanisms and applications of apolipoproteins and apolipoprotein mimetic peptides: Common pathways in cardiovascular disease and cancer	85
BubR1 and SIRT2: Insights into aneuploidy, aging, and cancer	84
Plant lectins and their usage in preparing targeted nanovaccines for cancer immunotherapy	83
Drivers of centrosome abnormalities: Senescence progression and tumor immune escape	81
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment	80

Functionalized-DNA nanostructures as potential targeted drug delivery systems for cancer therapy	79
Chaperonins in cancer: Expression, function, and migration in extracellular vesicles	79
Advancements in small cell lung cancer	78
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders	78
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	78
Clinical utility of whole-genome sequencing in precision oncology	77
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	76
The role of tumor microenvironment and exosomes in dormancy and relapse	75
Microbiota and lung cancer	74
Analytical demands to use whole-genome sequencing in precision oncology	73
Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent	72
MITOCHONDRIAL CHOLESTEROL AND CANCER	72
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases	72
Anticancer activity of lactic acid bacteria	71
Holistic immunomodulation for small cell lung cancer	71
Pattern recognition of tumor dormancy and relapse beyond cell-intrinsic and cell-extrinsic pathways	71
CRISPR/Cas mediated epigenome editing for cancer therapy	70
Targeting p53 for the treatment of cancer	70
Urinary microbiota and bladder cancer: A systematic review and a focus on uropathogens	69
Arsenic co-carcinogenesis: Inhibition of DNA repair and interaction with zinc finger proteins	68
Microbes in gynecologic cancers: Causes or consequences and therapeutic potential	68
Paradoxes of cancer: Survival at the brink	67
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme	67
Sanitation enzymes: Exquisite surveillance of the noncanonical nucleotide pool to safeguard the genetic blueprint	67
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	66
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	66
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer	66
Chemopreventive effects of anthocyanins on colorectal and breast cancer: A review	66
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	65
Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer	65
Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment	64
Editorial Board	64
Thematic issue ‘tumor glycolysis’	64
Excess body weight: Novel insights into its roles in obesity comorbidities	64
Special Issue: Epigenetic regulation of cancer progression: Promises and progress	64
Editorial Board	63
Editorial Board	63
Non-coding genome in small cell lung cancer between theoretical view and clinical applications	62
SR-BI as a target of natural products and its significance in cancer	61
The central role of mitochondria in the relationship between dietary lipids and cancer progression	61
The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives	60
Human cell polyploidization: The good and the evil	60
Beyond cell cycle regulation: The pleiotropic function of CDK4 in cancer	60
Deregulated transcription factors and poor clinical outcomes in cancer patients	60
Transfer RNA-derived small RNA: A rising star in oncology	59
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	59
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects	59
The impact of VEGF on cancer metastasis and systemic disease	58
TGF-β, EMT, and resistance to anti-cancer treatment	58
Characterizing and exploiting the many roles of aberrant H2B monoubiquitination in cancer pathogenesis	57
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges	57
The intricate role of adipokines in cancer-related signaling and the tumor microenvironment: Insights for future research	57
Role of endolysosome function in iron metabolism and brain carcinogenesis	56
Mechanisms and strategies of immunosenescence effects on non-small cell lung cancer (NSCLC) treatment: A comprehensive analysis and future directions	56
Editorial Board	56
Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer	56
Precision diagnostics in lymphomas – Recent developments and future directions	56
Possible connection between diet and microRNA in cancer scenario	56
Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers	56
The role of RNA-binding proteins in the processing of mRNAs produced by carcinogenic papillomaviruses	55
Inflammation-targeted nanomedicine against brain cancer: From design strategies to future developments	55
The Warburg effect: The hacked mitochondrial-nuclear communication in cancer	55
The intricate nature of senescence in development and cell plasticity	55
Putting the brakes on tumorigenesis with snake venom toxins: New molecular insights for cancer drug discovery	55
Remodeling of tumor microenvironment by cellular senescence and immunosenescence in cervical cancer	55
Extracellular vesicles as source for the identification of minimally invasive molecular signatures in glioblastoma	54
Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective	54
Contributions of the distinct biophysical phenotype of polyploidal giant cancer cells to cancer progression	54
Alternative splicing in EMT and TGF-β signaling during cancer progression	54
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	54
Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges	54
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	53
Transcriptional factors targeting in cancer stem cells for tumor modulation	53
cGAS/STING signalling pathway in senescence and oncogenesis	52
Artificial intelligence aids in development of nanomedicines for cancer management	52
Editorial Board	52
Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?	52
Gut microbiota and immunosenescence in cancer	52
Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology	52
Editorial Board	52

Regulation of cancer cell signaling pathways as key events for therapeutic relevance of edible and medicinal mushrooms	51
Vitamin D: What role in obesity-related cancer?	51
Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes	51
Corrigendum to “How far have we explored fungi to fight cancer?” [86/Part 2 (2022) 976–989]	51
Editorial Board	51
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis	50
Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs	50
The role of exercise in obesity-related cancers: Current evidence and biological mechanisms	49
The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community	49
A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer	49
New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy	49
Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications	48
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	48
The altered lipidome of hepatocellular carcinoma	48
Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)	47
Inflammation targeted nanomedicines: Patents and applications in cancer therapy	47
Precision medicine in pediatric solid cancers	47
Exploiting transcription factors to target EMT and cancer stem cells for tumor modulation and therapy	46
Small cell lung cancer: Novel treatments beyond immunotherapy	46
Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity	46
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	46
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	46
Pro-tumoral functions of tumor-associated macrophage EV-miRNA	46
Predictive biomarkers for response to immune checkpoint inhibition	45
“Time” for obesity-related cancer: The role of the circadian rhythm in cancer pathogenesis and treatment	45
Hedgehog signaling mechanism and role in cancer	45
Nanoparticles: Attractive tools to treat colorectal cancer	45